(AGFB) AGFA Gevaert - Ratings and Ratios
Exchange: BR • Country: Belgium • Currency: EUR • Type: Common Stock • ISIN: BE0003755692
AGFB: Imaging Systems, Printers, Inkjet Inks, X-ray Film, Healthcare Software
Agfa-Gevaert NV, a company with a rich history dating back to 1867, has evolved from its photographic roots to become a leader in digital and healthcare-related products. Headquartered in Mortsel, Belgium, the company operates through four key segments: Healthcare IT, Digital Print & Chemicals, Radiology Solutions, and CONOPS. Each segment contributes uniquely to the companys portfolio, with Healthcare IT offering workflow management solutions, Digital Print & Chemicals providing inkjet technologies for various applications, Radiology Solutions including specific imaging technologies like computed and digital radiography, and CONOPS supplying essential film and chemicals alongside support services.
Agfa-Gevaert NVs commitment to innovation is evident in its diverse product range, from enterprise imaging platforms to industrial inkjet inks and membranes for green hydrogen production. The companys strategic approach to integrating technology across different sectors underscores its adaptability and forward-thinking mindset.
Objective: Agfa-Gevaert NV aims to enhance its market position through continuous innovation and strategic expansion across its four core segments, leveraging its technical expertise and historical legacy to meet evolving market demands.
3-Month Forecast: Based on the provided data, the stock is expected to experience sideways movement with low volatility. Technically, the stock is below its 20-day SMA but above the 50-day SMA, indicating a potential consolidation phase. The low ATR suggests minimal price fluctuations. Fundamentally, while the negative RoE raises concerns about profitability, the low P/B ratio may attract value investors. The forward P/E of 13.04 suggests investor optimism, though tempered by current financial challenges. Overall, the forecast indicates cautious optimism with a focus on stability and potential undervaluation.
Additional Sources for AGFB Stock
AGFB Stock Overview
| Market Cap in USD | 155m |
| Sector | Industrials |
| Industry | Specialty Industrial Machinery |
| GiC Sub-Industry | Health Care Technology |
| IPO / Inception |
AGFB Stock Ratings
| Growth 5y | -89.2% |
| Fundamental | -34.0% |
| Dividend | 6.80% |
| Rel. Strength Industry | -20 |
| Analysts | - |
| Fair Price Momentum | 0.70 EUR |
| Fair Price DCF | - |
AGFB Dividends
| Dividend Yield 12m | 0.00% |
| Yield on Cost 5y | % |
| Annual Growth 5y | 0.00% |
| Payout Consistency | 22.7% |
AGFB Growth Ratios
| Growth Correlation 3m | 77.2% |
| Growth Correlation 12m | -90% |
| Growth Correlation 5y | -86.3% |
| CAGR 5y | -20.98% |
| CAGR/Max DD 5y | -0.24 |
| Sharpe Ratio 12m | -0.92 |
| Alpha | -39.76 |
| Beta | 1.27 |
| Volatility | 79.66% |
| Current Volume | 292.6k |
| Average Volume 20d | 134.8k |
As of March 16, 2025, the stock is trading at EUR 0.90 with a total of 292,607 shares traded.
Over the past week, the price has changed by +10.06%, over one month by -2.92%, over three months by +29.44% and over the past year by -19.33%.
Probably not. Based on ValueRay Fundamental Analyses, AGFA Gevaert (BR:AGFB) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -34.01 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AGFB as of March 2025 is 0.70. This means that AGFB is currently overvalued and has a potential downside of -22.22%.
AGFA Gevaert has no consensus analysts rating.
According to ValueRays Forecast Model, AGFB AGFA Gevaert will be worth about 0.8 in March 2026. The stock is currently trading at 0.90. This means that the stock has a potential downside of -8.89%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 1.3 | 47.8% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 0.8 | -8.9% |